

# Colorectal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C422EAC2B6D9EN.html>

Date: May 2024

Pages: 140

Price: US\$ 6,499.00 (Single User License)

ID: C422EAC2B6D9EN

## Abstracts

The 7 major colorectal cancer markets reached a value of US\$ 13.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 17.3 Billion by 2034, exhibiting a growth rate (CAGR) of 2.22% during 2024-2034.

The colorectal cancer market has been comprehensively analyzed in IMARC's new report titled "Colorectal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Colorectal cancer develops in the colon or rectum; depending on where they start, these malignancies are known as colon or rectal cancer. Since they have many common characteristics, colon and rectal cancers are sometimes grouped together. A majority of colorectal cancers begin as a growth on the interior lining of the colon or rectum, also known as polyps. Some common symptoms of colorectal cancer include changes in bowel patterns, such as constipation or diarrhea that lasts more than a few days, blood in the stool or rectal bleeding, stomach discomfort or cramping, etc. Other symptoms are unexplained weight loss, fatigue or weakness, a lump or mass in the abdomen, and an unusually low number of red blood cells. The diagnosis of colorectal cancer typically involves a combination of tests, including a rectal exam, colonoscopy, sigmoidoscopy, biopsy, stool DNA, CT colonography, barium enema X-ray imaging tests, such as CT scan and MRI, etc. The treatment options include surgery, radiation therapy, and chemotherapy. A combination of these therapies may be employed in some circumstances.

The escalating incidences of polyps or inflammatory bowel diseases, such as Crohn's disease or ulcerative colitis, are primarily driving the global colorectal cancer market. In addition to this, the rising prevalence of several associated risk factors, including smoking, alcohol consumption, taking a diet high in red or processed meats, etc., which

increase the likelihood of developing colorectal cancer, is also bolstering the market growth. Furthermore, the growing awareness regarding the early detection of colorectal cancer since it can enhance the chances of survival is creating a positive outlook for the market. Numerous screening tests, including stool-based tests and virtual colonoscopies, etc., are widely available to help detect colorectal cancer at an early stage. Besides this, the widespread adoption of combination therapy for improving treatment outcomes and reducing the risk of cancer relapse is also propelling the market growth. Moreover, the emerging popularity of precision medicine, which involves tailoring treatment to the specific genetic makeup of a person's tumor, thereby allowing for more targeted and effective treatment, is acting as another significant growth-inducing factor. Apart from this, the rising popularity of complementary and alternative therapies, such as acupuncture and herbal medicine, to help manage the side effects of colorectal cancer treatment and improve overall well-being is expected to drive the global colorectal cancer market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the colorectal cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for colorectal cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the colorectal cancer market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the colorectal cancer market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the colorectal cancer market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current colorectal cancer marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

### Key Questions Answered in this Report:

*Colorectal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2...*

## Market Insights

How has the colorectal cancer market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the colorectal cancer market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the colorectal cancer market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (2018-2034) of colorectal cancer across the seven major markets?

What is the number of prevalent cases (2018-2034) of colorectal cancer by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of colorectal cancer by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of colorectal cancer by type across the seven major markets?

How many patients are diagnosed (2018-2034) with colorectal cancer across the seven major markets?

What is the size of the colorectal cancer patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of colorectal cancer?

What will be the growth rate of patients across the seven major markets?

## Colorectal Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for colorectal cancer drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the colorectal cancer market?

What are the key regulatory events related to the colorectal cancer market?

What is the structure of clinical trial landscape by status related to the colorectal cancer market?

What is the structure of clinical trial landscape by phase related to the colorectal cancer market?

What is the structure of clinical trial landscape by route of administration related to the colorectal cancer market?

## Contents

### 1 PREFACE

### 2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### 3 EXECUTIVE SUMMARY

### 4 COLORECTAL CANCER - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### 5 COLORECTAL CANCER - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### 6 PATIENT JOURNEY

### 7 COLORECTAL CANCER - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

## 7.2 Epidemiology Scenario - Top 7 Markets

7.2.1 Epidemiology Scenario (2018-2023)

7.2.2 Epidemiology Forecast (2024-2034)

7.2.3 Epidemiology by Age (2018-2034)

7.2.4 Epidemiology by Gender (2018-2034)

7.2.5 Epidemiology by Type (2018-2034)

7.2.6 Diagnosed Cases (2018-2034)

7.2.7 Patient Pool/Treated Cases (2018-2034)

## 7.3 Epidemiology Scenario - United States

7.3.1 Epidemiology Scenario (2018-2023)

7.3.2 Epidemiology Forecast (2024-2034)

7.3.3 Epidemiology by Age (2018-2034)

7.3.4 Epidemiology by Gender (2018-2034)

7.3.5 Epidemiology by Type (2018-2034)

7.3.6 Diagnosed Cases (2018-2034)

7.3.7 Patient Pool/Treated Cases (2018-2034)

## 7.4 Epidemiology Scenario - Germany

7.4.1 Epidemiology Scenario (2018-2023)

7.4.2 Epidemiology Forecast (2024-2034)

7.4.3 Epidemiology by Age (2018-2034)

7.4.4 Epidemiology by Gender (2018-2034)

7.4.5 Epidemiology by Type (2018-2034)

7.4.6 Diagnosed Cases (2018-2034)

7.4.7 Patient Pool/Treated Cases (2018-2034)

## 7.5 Epidemiology Scenario - France

7.5.1 Epidemiology Scenario (2018-2023)

7.5.2 Epidemiology Forecast (2024-2034)

7.5.3 Epidemiology by Age (2018-2034)

7.5.4 Epidemiology by Gender (2018-2034)

7.5.5 Epidemiology by Type (2018-2034)

7.5.6 Diagnosed Cases (2018-2034)

7.5.7 Patient Pool/Treated Cases (2018-2034)

## 7.6 Epidemiology Scenario - United Kingdom

7.6.1 Epidemiology Scenario (2018-2023)

7.6.2 Epidemiology Forecast (2024-2034)

7.6.3 Epidemiology by Age (2018-2034)

7.6.4 Epidemiology by Gender (2018-2034)

7.6.5 Epidemiology by Type (2018-2034)

7.6.6 Diagnosed Cases (2018-2034)

#### 7.6.7 Patient Pool/Treated Cases (2018-2034)

### 7.7 Epidemiology Scenario - Italy

#### 7.7.1 Epidemiology Scenario (2018-2023)

#### 7.7.2 Epidemiology Forecast (2024-2034)

#### 7.7.3 Epidemiology by Age (2018-2034)

#### 7.7.4 Epidemiology by Gender (2018-2034)

#### 7.7.5 Epidemiology by Type (2018-2034)

#### 7.7.6 Diagnosed Cases (2018-2034)

#### 7.7.7 Patient Pool/Treated Cases (2018-2034)

### 7.8 Epidemiology Scenario - Spain

#### 7.8.1 Epidemiology Scenario (2018-2023)

#### 7.8.2 Epidemiology Forecast (2024-2034)

#### 7.8.3 Epidemiology by Age (2018-2034)

#### 7.8.4 Epidemiology by Gender (2018-2034)

#### 7.8.5 Epidemiology by Type (2018-2034)

#### 7.8.6 Diagnosed Cases (2018-2034)

#### 7.8.7 Patient Pool/Treated Cases (2018-2034)

### 7.9 Epidemiology Scenario - Japan

#### 7.9.1 Epidemiology Scenario (2018-2023)

#### 7.9.2 Epidemiology Forecast (2024-2034)

#### 7.9.3 Epidemiology by Age (2018-2034)

#### 7.9.4 Epidemiology by Gender (2018-2034)

#### 7.9.5 Epidemiology by Type (2018-2034)

#### 7.9.6 Diagnosed Cases (2018-2034)

#### 7.9.7 Patient Pool/Treated Cases (2018-2034)

## **8 COLORECTAL CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

### 8.1 Guidelines, Management and Treatment

### 8.2 Treatment Algorithm

## **9 COLORECTAL CANCER - UNMET NEEDS**

## **10 COLORECTAL CANCER - KEY ENDPOINTS OF TREATMENT**

## **11 COLORECTAL CANCER - MARKETED PRODUCTS**

### 11.1 List of Colorectal Cancer Marketed Drugs Across the Top 7 Markets



- 11.1.1 Vectibix (Panitumumab) – Amgen
  - 11.1.1.1 Drug Overview
  - 11.1.1.2 Mechanism of Action
  - 11.1.1.3 Regulatory Status
  - 11.1.1.4 Clinical Trial Results
  - 11.1.1.5 Sales Across Major Markets
- 11.1.2 Avastin (Bevacizumab) - Genentech/Roche
  - 11.1.2.1 Drug Overview
  - 11.1.2.2 Mechanism of Action
  - 11.1.2.3 Regulatory Status
  - 11.1.2.4 Clinical Trial Results
  - 11.1.2.5 Sales Across Major Markets
- 11.1.3 Stivarga (Regorafenib) - Bayer Healthcare
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Zaltrap (Aflibercept) – Bayer/Regeneron Pharmaceuticals/Sanofi
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Erbitux (Cetuximab) - Eli Lilly and Company
  - 11.1.5.1 Drug Overview
  - 11.1.5.2 Mechanism of Action
  - 11.1.5.3 Regulatory Status
  - 11.1.5.4 Clinical Trial Results
  - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 COLORECTAL CANCER - PIPELINE DRUGS**

- 12.1 List of Colorectal Cancer Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 XL 092 - Exelixis
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action

- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status
- 12.1.2 MRTX849 - Mirati Therapeutics
  - 12.1.2.1 Drug Overview
  - 12.1.2.2 Mechanism of Action
  - 12.1.2.3 Clinical Trial Results
  - 12.1.2.4 Safety and Efficacy
  - 12.1.2.5 Regulatory Status
- 12.1.3 MK4280A - Merck Sharp & Dohme
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status
- 12.1.4 Napabucasin - Sumitomo Pharma Oncology
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status
- 12.1.5 Sotorasib - Amgen
  - 12.1.5.1 Drug Overview
  - 12.1.5.2 Mechanism of Action
  - 12.1.5.3 Clinical Trial Results
  - 12.1.5.4 Safety and Efficacy
  - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. COLORECTAL CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. COLORECTAL CANCER – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 COLORECTAL CANCER - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Colorectal Cancer - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Colorectal Cancer - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Colorectal Cancer - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Colorectal Cancer - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

#### 15.3.3 Colorectal Cancer - Access and Reimbursement Overview

### 15.4 Market Scenario - Germany

#### 15.4.1 Colorectal Cancer - Market Size

##### 15.4.1.1 Market Size (2018-2023)

##### 15.4.1.2 Market Forecast (2024-2034)

#### 15.4.2 Colorectal Cancer - Market Size by Therapies

##### 15.4.2.1 Market Size by Therapies (2018-2023)

##### 15.4.2.2 Market Forecast by Therapies (2024-2034)

#### 15.4.3 Colorectal Cancer - Access and Reimbursement Overview

### 15.5 Market Scenario - France

#### 15.5.1 Colorectal Cancer - Market Size

##### 15.5.1.1 Market Size (2018-2023)

##### 15.5.1.2 Market Forecast (2024-2034)

#### 15.5.2 Colorectal Cancer - Market Size by Therapies

##### 15.5.2.1 Market Size by Therapies (2018-2023)

##### 15.5.2.2 Market Forecast by Therapies (2024-2034)

#### 15.5.3 Colorectal Cancer - Access and Reimbursement Overview

### 15.6 Market Scenario - United Kingdom

#### 15.6.1 Colorectal Cancer - Market Size

##### 15.6.1.1 Market Size (2018-2023)

##### 15.6.1.2 Market Forecast (2024-2034)

- 15.6.2 Colorectal Cancer - Market Size by Therapies
  - 15.6.2.1 Market Size by Therapies (2018-2023)
  - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Colorectal Cancer - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Colorectal Cancer - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Colorectal Cancer - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Colorectal Cancer - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Colorectal Cancer - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Colorectal Cancer - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Colorectal Cancer - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Colorectal Cancer - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Colorectal Cancer - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Colorectal Cancer - Access and Reimbursement Overview

## **16 COLORECTAL CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 COLORECTAL CANCER MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 COLORECTAL CANCER MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Colorectal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C422EAC2B6D9EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C422EAC2B6D9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

